Robertson JF - Search Results

1

The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.

Robertson JF, Blamey RW. Robertson JF, et al. Eur J Cancer. 2003 May;39(7):861-9. doi: 10.1016/s0959-8049(02)00810-9. Eur J Cancer. 2003. PMID: 12706354 Review.

2

Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.

Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thürlimann B. Nabholtz JM, et al. Among authors: robertson jf. Eur J Cancer. 2003 Aug;39(12):1684-9. doi: 10.1016/s0959-8049(03)00326-5. Eur J Cancer. 2003. PMID: 12888362 Clinical Trial.

3

Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features.

James JJ, Evans AJ, Pinder SE, Gutteridge E, Cheung KL, Chan S, Robertson JF. James JJ, et al. Among authors: robertson jf. Br J Cancer. 2003 Aug 18;89(4):660-5. doi: 10.1038/sj.bjc.6601198. Br J Cancer. 2003. PMID: 12915874 Free PMC article.

4

Spindle cell carcinoma of the breast: a case series of a rare histological subtype.

Khan HN, Wyld L, Dunne B, Lee AH, Pinder SE, Evans AJ, Robertson JF. Khan HN, et al. Among authors: robertson jf. Eur J Surg Oncol. 2003 Sep;29(7):600-3. doi: 10.1016/s0748-7983(03)00107-0. Eur J Surg Oncol. 2003. PMID: 12943626

5

Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.

Thürlimann B, Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J; Arimidex Study Group. Thürlimann B, et al. Among authors: robertson jf. Eur J Cancer. 2003 Nov;39(16):2310-7. doi: 10.1016/s0959-8049(03)00602-6. Eur J Cancer. 2003. PMID: 14556922

6

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

Forward DP, Cheung KL, Jackson L, Robertson JF. Forward DP, et al. Among authors: robertson jf. Br J Cancer. 2004 Feb 9;90(3):590-4. doi: 10.1038/sj.bjc.6601557. Br J Cancer. 2004. PMID: 14760369 Free PMC article. Clinical Trial.

7

Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?

Rampaul RS, Pinder SE, Wencyk PM, Nicholson RI, Blamey RW, Robertson JF, Ellis IO. Rampaul RS, et al. Among authors: robertson jf. Clin Cancer Res. 2004 Apr 1;10(7):2578. Clin Cancer Res. 2004. PMID: 15073139 No abstract available.

8

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.

Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Abd El-Rehim DM, et al. Among authors: robertson jf. Br J Cancer. 2004 Oct 18;91(8):1532-42. doi: 10.1038/sj.bjc.6602184. Br J Cancer. 2004. PMID: 15480434 Free PMC article.

9

Endocrine treatment options for advanced breast cancer--the role of fulvestrant.

Robertson JF, Come SE, Jones SE, Beex L, Kaufmann M, Makris A, Nortier JW, Possinger K, Rutqvist LE. Robertson JF, et al. Eur J Cancer. 2005 Feb;41(3):346-56. doi: 10.1016/j.ejca.2004.07.035. Eur J Cancer. 2005. PMID: 15691633 Review.

10

Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.

Robertson JF, Howell A, Gorbunova VA, Watanabe T, Pienkowski T, Lichinitser MR. Robertson JF, et al. Breast Cancer Res Treat. 2005 Jul;92(2):169-74. doi: 10.1007/s10549-004-4776-0. Breast Cancer Res Treat. 2005. PMID: 15986127

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

370 results

Search Page

Filters